Lipidomics services to reach your research goals.

SOPHIA aims to enable healthcare professionals to reliably predict the complications of obesity and who will respond to treatment. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875534. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, and Obesity Action Coalition.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881 (RHAPSODY). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2. The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974 (Beat-DKD). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2. The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.

ISLET is a European project spearheaded by a unique team of scientists that share an ambitious common goal: to pioneer a new advanced cell therapy for Type 1 Diabetes. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 874839 ISLET.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874753.

Lipotype GmbH is supported and receives funding by the German Federal Ministry of Education and Research and the BMBF innovation initiative “Entrepreneurial Regions” („Unternehmen Region“) for the New German Länder within the project Praemed.Bio.

KOMA BIOTECH provides a broad spectrum of reagents, kits and technologies for life science research including lipidomics analysis services.

Shigematsu & Co. Ltd. imports a variety of research chemicals, HTS compound libraries, building blocks, intermediates, antibodies and analysis services, and supplies them to the leading pharmaceutical companies, universities, and government- and privately-owned institutes in Japan.

Taiwan-BioActive Lipid (T-BAL) is the first company in Taiwan to provide full lipid metabolomics measurement services. In the era of genomic detection, T-BAL serves to provide accurate health testing, define accurate health indicators, and provide a full range of accurate health guidance.

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.

biosaxony is the Saxon association of the biotechnology and medical technology sector.

DiagnostikNet-BB bundles the competencies of diagnostics companies, users from clinics and laboratories as well as scientific research institutes from the Berlin-Brandenburg region. The network accelerates the turnaround of ideas to become marketable innovations along the entire value-added chain of IVD.

The Anfibio Packrafting Store is the exclusive provider of Lipotype’s iconic Lipid Raft. They are dedicated to the concept of Packrafting as much as we are dedicated to claiming to be the world champions in lipid rafting!